secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jounce Therapeutics, Inc. (—)
CIK:        0001640455
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001640455-23-000018
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.05, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jounce Therapeutics to combine with Redx Pharma in all-share deal; Redx shareholders to own 63% of combined company
--------------------------------------------------------------------------------

- Redx shareholders receive 0.2105 Jounce shares per Redx share; combined company ownership: 63% Redx, 37% Jounce.
- Workforce reduced by ~57%; estimated $11.2M pre-tax charges in Q1 2023.
- CEO Richard Murray steps down March 31, 2023; COO Hugh Cole steps down March 15, 2023; CFO Kim Drapkin becomes Interim President.
- Contingent Value Rights (CVRs) issued to Jounce shareholders for potential payments from future disposition of pipeline assets (JTX-8064, pimivalimab, etc.) within one year.
- Redx shareholders representing 76.6% of Redx shares and Jounce shareholders representing 21.3% of Jounce shares have agreed to support the deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640455/000164045523000018/0001640455-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640455/000164045523000018/jnce-20230222.htm
  HTML page:      https://secwatch.observer/filing/0001640455-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer